Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax After TKI to Target Persisting Stem Cells in CML
NCT05701215Phase 2Completed
- Start
- Aug 2023
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in chronic myeloid leukemia (CML). Primary endpoint: Stem cell change at 12 months. Started Aug 2023; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05701215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701215.